Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects, aged 18 years or older with unresectable or metastatic melanoma.~* A life expectancy of \>12 weeks.~* Laboratory ranges and medical criteria met, as defined within the protocol.~* Subject may have received more than 1 prior regimen of systematic treatment for unresectable or metastatic melanoma.~* For Phase 2 period of the study only, Subjects must have archival tumor tissue available and collected with the prior 6 months or accessible disease for pre-treatment, study biopsy.~Exclusion Criteria:~* Pregnant or nursing women.~* Current investigational trial participation with another investigational product or subjects who have received any anticancer medications within 21 days prior to screening (6 weeks for mitomycin-C or nitrosoureas.)~* Subjects receiving monoamine oxidase inhibitors (MAOI)s; subjects who have ever had Serotonin Syndrome after receiving one or more serotonergic drugs.~* Subjects who have received prior immune checkpoint inhibitors (eg anti-CTLA-4, anti-PD-1, anti- PD-L1 and others) who have had Grade 3 or 4 hepatotoxicity, immune colitis requiring infliximab, endocrine toxicity not controlled by replacement, any other Grade 4 immune adverse events (AEs) or ocular toxicity~* Subjects with protocol-specified active autoimmune process except vitiligo or thyroiditis.~* Subjects with concurrent conditions that would jeopardize the safety of the safety of the subject or compliance with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Epacadostat 300 mg (Type: EXPERIMENTAL): 300 mg twice daily (BID) in combination with ipilimumab
- Placebo in combination with ipilimumab (Type: PLACEBO_COMPARATOR): None
- Epacadostat 25 mg (Type: EXPERIMENTAL): 25 mg BID in combination with ipilimumab
- Epacadostat 50 mg (Type: EXPERIMENTAL): 50 mg BID in combination with ipilimumab
- Epacadostat 75 mg (Type: EXPERIMENTAL): 75 mg once a day (QD) in combination with ipilimumab

Based on this trial design, predict the completion outcome and termination type (if applicable).